Introduction:
Pharma stock has signed a 10-year Manufacturing & Supply Agreement with a top US and European distributor. This deal strengthens its global presence, leveraging USFDA-approved facilities to expand contract manufacturing, enhance R&D capabilities, and drive growth in regulated markets.
Share Price movement of Medicamen Biotech:
On February 20, 2025, Medicamen Biotech Ltd opened at ₹494.00, reaching a high of ₹524.00, up 5.06% from its previous close of ₹496.80, and a low of ₹492.35. Currently, it is trading at ₹521.95, with a market cap of ₹663.64 crore.
Medicamen Biotech made a new agreement:
Medicamen Biotech Limited signed a 10-year Manufacturing & Supply Agreement with a leading US and European pharma distributor. The company will manufacture products as per partner specifications. This deal strengthens Medicamen’s global presence and enhances its contract manufacturing capabilities.
The agreement involves contract manufacturing at Medicamen’s USFDA-approved Oncology Unit. The company will receive 25% of the payment upon signing. This collaboration highlights Medicamen’s advanced R&D expertise and financial viability while expanding its footprint in international pharmaceutical markets.
Utilizing its strong manufacturing infrastructure, Medicamen will provide value-added custom manufacturing services. The deal supports expansion into regulated markets and drives revenue growth. This agreement reinforces Medicamen’s position as a key global pharmaceutical supplier.
Also Read: 5 Stocks that hit 20% upper circuit today; Do you own any?
Recent news About Medicamen Biotech :
On November 16, 2024, Medicamen Biotech Limited announced that its sterile oncology facility received USFDA approval, enabling expansion into regulated markets such as the U.S. and the Middle East. This milestone reflects the company’s commitment to delivering high-quality oncology treatments globally.
Ace investor holding of Medicamen Biotech:
Ace investor Ashish Chugh holds 135,171 shares of Medicamen Biotech Ltd, representing a 1.06% stake valued at ₹7.0 crore. His consistent holding signals confidence in the company’s growth prospects, highlighting its potential in the pharmaceutical sector and long-term investment appeal.
Stock performance of Medicamen Biotech for Period of 1 week, 6 months and 1 year:
Medicamen Biotech’s stock rose by 5.94% over the past week. Over six months, it gained 21.6%, indicating steady growth. The one-year performance also showed a 5.94% increase, highlighting consistent upward momentum and positive investor sentiment in the pharmaceutical sector.
Also Read: Auto stock jumps 3% after receiving order to supply 320 diesel fuel busses from Tamil Nadu Govt
Shareholding pattern of Medicamen Biotech:
| All values in % | Dec-24 | Sep-24 | Jun-24 |
| Promoters | 42.99 | 42.99 | 42.99 |
| FII | 0.06 | 0.06 | 0.06 |
| DII | 0.87 | 1.17 | 1.17 |
| Retail & others | 56.1 | 55.79 | 55.78 |
About Medicamen Biotech:
Medicamen Biotech is a pharmaceutical company specializing in the manufacturing of formulations and APIs, with a strong focus on oncology and regulated markets. With USFDA-approved facilities, it caters to global clients, offering high-quality medicines while expanding its presence in international markets.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
